Blood: Immunomodulator molecular target CRBN regulates CD8-T cell activation

Immunomodulating drugs, such as thalidomide and related compounds, enhance the function of effectT T cellsCereblon (CRBN), a matrix receptor of the DDB1-cullin-RING E3 ubiquitin-connected enzyme complex, is also the only known molecular target for such drugs;but it is still far from clear whether these Cereblon E3 connective enzyme-regulating compounds disrupt the endogenous function of CRBNin this paper, the researchers reported on the role of CRBN in the feedback loop of the reaction using antigen-specific CD8-T cell effectspecifically, the lack of CD8-T cell CRBN in mice enhanced their central metabolism, as evidenced by increased bioenergy, increased polyamine hyperphysiological levels after increased glucose and amino acid transport, and increased expression of metabolic enzymes, including Ornithine Childylaseimportant, the treatment with Celeblon regulatory compounds can similarly enhance the central metabolism of human CD8-T cellsIt is worth noting that the lack of metabolic regulation of CD8-T cells by regulating compounds or CRBN is associated with the increase and continuous expression of myC, the main metabolic regulatorfinally, both in vitro and in vitro, CRBN-defective T-cells have enhanced antigen-specific cell dissolution activity for melanoma cells and can promote accelerated high-invasive graft resistance to host disease, the function of CRBN is to regulate the activation of CD8-T cells, the phenotypes can be regulated by the drug